Stocks Ended Lower Yesterday, Bank Fears Weighed, While Investors Cheered Better Than Expected PPI

A recent breakthrough in biotech is changing the way we approach medicine. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Unsubscribe A Message from Behind the Markets Dear Fellow Investor, A recent breakthrough in biotech is changing the way we approach medicine. This new technique allows researchers to essentially "Cut & Paste" disease from a patient. One company is already in clinical trials with a liver cancer candidate. Another is filing for trials this year on muscular dystrophy and blindness. These are biotechs that barely anyone has heard of... yet they're still pioneering epigenetic breakthroughs. Make no mistake - this is the future of genetic medicine... and it's unfolding rapidly. The global market is projected to explode to $6.35 billion by 2032. Don't miss out as the next genetic blockbuster emerges from the shadows. Get the full story here >>> "The Buck Stops Here," Dylan Jovine, CEO & Founder Behind the Markets

This message is a paid advertisement sent on behalf of Behind the Markets, a third-party advertiser of MarketBeat. Why did I receive this email?   If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.   If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.   © 2006-2024 MarketBeat Media, LLC. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.   Today's Bonus Content: This is a huge income gap many folks can't fill right now (Click to Opt-in)